Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 7/20 | 0.44 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 6/20 | 0.39 |
| ▸ | CPA1 | P15085 | 2/20 | 0.38 |
| ▸ | CPA2 | P48052 | 2/20 | 0.38 |
| ▸ | CPA4 | Q9UI42 | 2/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493308 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CAPN1PSMB1PSMB5PSMB2 | |
| SCHEMBL7510270 | 0.98 | ALDH1A1 (0.53) | ALDH1A1CAPN1PSMB1PSMB5PSMB2 | |
| SCHEMBL3866137 | 0.98 | ALDH1A1 (0.53) | ALDH1A1CAPN1PSMB1PSMB5PSMB2 | |
| SCHEMBL9542347 | 0.98 | ALDH1A1 (0.53) | ALDH1A1CAPN1PSMB1PSMB5PSMB2 | |
| SCHEMBL29536183 | 0.86 | CAPN1 (0.47) | ALDH1A1CAPN1PSMB1PSMB5PSMB2 | |
| SCHEMBL5570286 | 0.86 | CAPN1 (0.47) | ALDH1A1CAPN1PSMB1PSMB5PSMB2 | |
| SCHEMBL7039371 | 0.86 | ALDH1A1 (0.47) | ALDH1A1PSMB1PSMB5PSMB2CTSB | |
| SCHEMBL7039386 | 0.86 | ALDH1A1 (0.47) | ALDH1A1PSMB1PSMB5PSMB2CTSB | |
| SCHEMBL7974645 | 0.85 | ALDH1A1 (0.50) | ALDH1A1CAPN1CTSBCTSK | |
| SCHEMBL2995716 | 0.85 | ALDH1A1 (0.50) | ALDH1A1CAPN1CTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214664-B2 | Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060135438-A1 | Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-22 | — | — | US | disclosed |
| EP-1608410-A2 | PHARMICO-GENE THERAPHY OF EPITHELIAL SODIUM CHANNEL ASSOCIATED DISODERS | University of Iowa Research Foundation (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004089423-A2 | PHARMICO-GENE THERAPHY OF EPITHELIAL SODIUM CHANNEL ASSOCIATED DISODERS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-0910632-A2 | PRESENTATION OF ANTIGEN, INTRODUCED INTO THE CELLS BY STIMULATION OF MACROPINOCYTOSIS | THE UNIVERSITY OF DUNDEE, UNIVERSITY COURT (GB) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997023607-A2 | PRESENTATION OF ANTIGEN, INTRODUCED INTO CELLS BY STIMULATION OF MACROPINOCYTOSIS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135438-A1 | Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux | ABCB1, SLC1A5, ABCC1 | ALDH1A1 4085/4885CAPN1 723/4885PSMB1 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.